Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Genentech has released results from a multicenter, randomized, double-blind, placebo-controlled Phase III OCEANS study investigating Avastin (bevacizumab), in conjunction with chemotherapy (gemcitabine and carboplatin), following continuous usage of Avastin alone in women with previously treated (recurrent) platinum-sensitive ovarian cancer.
Subscribe to our email newsletter
Avastin is a prescription-only medicine that is a solution for intravenous infusion.
In the trial, the women who received Avastin showed 52% reduction in the risk of their disease progressing as compared to women who received chemotherapy alone.
Additionally, the results from the trial also suggested tumor shrinkage (overall response rate) in 79% of women receiving the Avastin-based regimen compared to 57% of women who received chemotherapy alone.
Genentech Global Product Development chief medical officer and head Hal Barron said these data add to the growing body of evidence supporting Avastin’s potential role in this disease, which includes two previously presented Phase III clinical trials in women with newly diagnosed ovarian cancer.